Indaptus Therapeutics Inc
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency… Read more
Indaptus Therapeutics Inc (INDP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.663x
Based on the latest financial reports, Indaptus Therapeutics Inc (INDP) has a cash flow conversion efficiency ratio of -0.663x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.05 Million) by net assets ($4.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Indaptus Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Indaptus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Indaptus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Indaptus Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pucara Gold Ltd
PINK:PCRAF
|
-0.236x |
|
Prima Globalindo Logistik Tbk
JK:PPGL
|
0.060x |
|
EGDB11
SA:EGDB11
|
N/A |
|
Integrated Media Technology Ltd
NASDAQ:IMTE
|
0.341x |
|
SandRidge Mississippian Trust I
PINK:SDTTU
|
0.080x |
|
K.B. Recycling Industries Ltd
OTCQB:AKMYF
|
1.301x |
|
CARDINAL HEALTH
MU:CLH
|
0.503x |
|
Kim Hin Industry Bhd
KLSE:5371
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Indaptus Therapeutics Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Indaptus Therapeutics Inc from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.94 Million | $-12.32 Million | -3.124x | -181.42% |
| 2023-12-31 | $12.08 Million | $-13.41 Million | -1.110x | -109.05% |
| 2022-12-31 | $24.63 Million | $-13.08 Million | -0.531x | -68.83% |
| 2021-12-31 | $35.90 Million | $-11.29 Million | -0.315x | -102.25% |
| 2020-12-31 | $-237.70K | $-3.32 Million | 13.987x | +655.47% |
| 2019-12-31 | $11.54 Million | $-29.05 Million | -2.518x | -245.03% |
| 2018-12-31 | $53.55 Million | $-39.08 Million | -0.730x | -93.89% |
| 2017-12-31 | $58.80 Million | $-22.13 Million | -0.376x | +28.82% |
| 2016-12-31 | $22.70 Million | $-12.01 Million | -0.529x | -137.68% |
| 2015-12-31 | $35.63 Million | $-7.93 Million | -0.222x | +55.64% |
| 2014-12-31 | $9.48 Million | $-4.75 Million | -0.501x | -37.70% |
| 2013-12-31 | $9.30 Million | $-3.38 Million | -0.364x | +44.59% |
| 2012-12-31 | $6.85 Million | $-4.50 Million | -0.657x | +5.12% |
| 2011-12-31 | $7.77 Million | $-5.38 Million | -0.693x | -84.96% |
| 2010-12-31 | $11.51 Million | $-4.31 Million | -0.375x | +80.86% |
| 2009-12-31 | $1.57 Million | $-3.08 Million | -1.957x | -208.82% |
| 2008-12-31 | $-2.10 Million | $-3.78 Million | 1.798x | -- |